IP Library Granted Patent US 11,779,482
Granted Patent B2
US 11,779,482 · App. 17/581,792 · Granted Oct 10, 2023

Intragastric device

Inventors: Mark C. Brister (Encinitas, CA); Paul D. Faucher (Escondido, CA); Neil R. Drake (San Diego, CA); Andrew P. Rasdal (San Diego, CA); Matthew S. Lake (Carlsbad, CA); Dubravka Markovic (San Diego, CA); Amy D. L. VandenBerg (San Diego, CA); Antonio C. Llevares (Chula Vista, CA); Josefina Nider (San Diego, CA)
Assignee: ReShape Lifesciences Inc.
A61F5/003A61F5/0036A61F5/0089A61M25/10181A61M29/02A61M25/10185
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,482
App. No.
17/581,792
Granted
Oct 10, 2023
Kind
B2
Abstract

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Claims (23)

1. An intragastric balloon system, comprising:

a capsule configured to be swallowable by a patient by normal peristalsis and to degrade in a gastric environment;

a balloon compacted and contained within the capsule, the balloon including an outer surface, an inner surface, an interior cavity, a fill valve, and a release valve, wherein the fill valve and the release valve are separate valves;

a catheter configured to be coupled to the fill valve, wherein

after the patient swallows the capsule, a first portion of the catheter is configured to remain outside the patient's mouth and a second portion of the catheter is configured to remain in the patient while the catheter is coupled to the fill valve,

the catheter is further configured to deliver a saline liquid through the fill valve to the interior cavity of the balloon for inflating the balloon with the saline liquid when the balloon is in the patient's stomach, and

the catheter is further configured to be detached from the fill valve after inflating the balloon with the saline liquid; and

wherein the fill valve is a self-sealing valve that is configured to self-seal after the catheter is detached from the fill valve;

wherein at least a degradable portion of the release valve is configured to degrade in an internal environment of the interior cavity of the balloon when the saline liquid is in the interior cavity of the balloon and in response to the saline liquid being in contact with the degradable portion of the release valve; and wherein when the saline liquid is in the interior cavity of the balloon, the degradable portion of the release valve is configured to be degraded by contact with the saline liquid such that the degradation opens the release valve to allow the saline liquid to travel from the interior cavity of the balloon into the gastric environment thereby deflating the balloon.

2. The intragastric balloon system of claim 1 , wherein the degradable portion of the release valve is configured to degrade in the internal environment of the interior cavity of the balloon and thereby open the release valve at approximately between 1 month and 6 months after inflating the balloon with the saline liquid.

3. The intragastric balloon system of claim 1 , wherein the degradable portion of the release valve is configured to degrade in the internal environment of the interior cavity of the balloon and thereby open the release valve at approximately 3 months after inflating the balloon with the saline liquid.

4. The intragastric balloon system of claim 1 , wherein the deflated balloon is configured to pass through the remainder of the patient's digestive tract.

5. The intragastric balloon system of claim 1 , further comprising a liquid container configured to couple to the catheter and supply the saline liquid to the catheter for inflating the balloon.

6. The intragastric balloon system of claim 1 , wherein the catheter is configured to be detached from the fill valve of the balloon after the balloon is filled or inflated with the saline liquid by pulling back the first portion or the second portion of the catheter.

7. The intragastric balloon system of claim 1 , wherein at approximately between 1 month and 6 months after inflating the balloon with the saline liquid, the degradable portion of the release valve is configured to degrade and allow the saline liquid to drain from the interior cavity of the balloon.

8. The intragastric balloon system of claim 1 , wherein the balloon is configured to transit a gastrointestinal tract and be excreted after the balloon is deflated.

9. The intragastric balloon system of claim 1 , wherein the interior cavity is defined by the inner surface of the balloon.

10. The intragastric balloon system of claim 1 , wherein the release valve comprises an erodible core.

11. The intragastric balloon system of claim 1 , wherein the release valve comprises a degradable patch.

12. The intragastric balloon system of claim 1 , wherein the outer surface of the balloon separates the gastric environment from the release valve.

13. The intragastric balloon system of claim 1 , wherein the compacted balloon is configured to contain no liquid before the patient swallows the capsule.

14. The intragastric balloon system of claim 1 , further comprising the saline liquid.

15. The intragastric balloon system of claim 1 , wherein the release valve includes an erodible seam.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2025
From: RESHAPE LIFESCIENCES INC.
To: MEDTIMO INC.
Reel/Frame 072955/0766 →
SECURITY INTEREST Recorded Oct 24, 2024
From: RESHAPE LIFESCIENCES INC.
To: ASCENT PARTNERS FUND LLC
Reel/Frame 070166/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2023
From: BRISTER, MARK C.; FAUCHER, PAUL D.; DRAKE, NEIL R.; RASDAL, ANDREW P.; LAKE, MATTHEW S.; MARKOVIC, DEBRAVKA; VANDENBERG, AMY D.L.; LLEVARES, ANTONIO C.; NIDER, JOSEFINA
To: OBALON THERAPEUTICS INC.
Reel/Frame 064526/0714 →
CHANGE OF NAME Recorded Aug 8, 2023
From: OBALON THERAPEUTICS INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 064526/0920 →
Continuity (7)
Continuation 16792094 · Feb 14, 2020
Continuation 15906942 · Feb 27, 2018
Continuation 15690095 · Aug 29, 2017
Continuation 14860538 · Sep 21, 2015
Continuation 14227195 · Mar 27, 2014
Continuation 13510921
Related Publication 20220218505A1 · Jul 14, 2022